Eiger BioPharmaceuticals, Inc. financial data

Symbol
EIGR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2155 Park Boulevard, Palo Alto, California
Fiscal year end
December 31
Former names
Celladon Corp (to 3/23/2016)
Latest financial report
Q4 2023 - Apr 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 235 % -54.3%
Quick Ratio 8.23 % -13.6%
Debt-to-equity 672 % +808%
Return On Equity -870 % -650%
Return On Assets -113 % -69.1%
Operating Margin -688 % -8.54%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.48 M shares -96.6%
Common Stock, Shares, Outstanding 1.48 M shares +0.7%
Entity Public Float 30 M USD -89.1%
Common Stock, Value, Issued 1 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 1.48 M shares +6.39%
Weighted Average Number of Shares Outstanding, Diluted 1.48 M shares +6.39%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 3.21 M USD -20.3%
Cost of Revenue 115 K USD -90.7%
Research and Development Expense 62.3 M USD -17.2%
Costs and Expenses 87.6 M USD -17.6%
Operating Income (Loss) -71.8 M USD +22.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -75 M USD +22.5%
Income Tax Expense (Benefit) 6 K USD -73.9%
Net Income (Loss) Attributable to Parent -75 M USD +22.5%
Earnings Per Share, Basic -50.8 USD/shares +27.2%
Earnings Per Share, Diluted -50.8 USD/shares +27.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.4 M USD -1.39%
Cash, Cash Equivalents, and Short-term Investments 39.4 M USD -67.4%
Inventory, Net 1.56 M USD -45.5%
Assets, Current 37.8 M USD -67.8%
Property, Plant and Equipment, Net 627 K USD -9.91%
Operating Lease, Right-of-Use Asset 209 K USD -15%
Other Assets, Noncurrent 360 K USD -81.1%
Assets 38.8 M USD -67.7%
Accounts Payable, Current 2.12 M USD -76.4%
Accrued Liabilities, Current 9.97 M USD -36.3%
Liabilities, Current 53.3 M USD +112%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 53.3 M USD -17.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -169 K USD +43.7%
Retained Earnings (Accumulated Deficit) -512 M USD -17.1%
Stockholders' Equity Attributable to Parent -14.5 M USD -126%
Liabilities and Equity 38.8 M USD -67.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24 M USD -30%
Net Cash Provided by (Used in) Financing Activities 41 K USD -99.9%
Net Cash Provided by (Used in) Investing Activities 13.4 M USD
Common Stock, Shares Authorized 200 M shares 0%
Common Stock, Shares, Issued 1.48 M shares +0.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.6 M USD -144%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.4 M USD -1.39%
Interest Paid, Excluding Capitalized Interest, Operating Activities 920 K USD +34.1%
Deferred Tax Assets, Valuation Allowance 117 M USD +21.2%
Deferred Tax Assets, Gross 117 M USD +21%
Operating Lease, Liability 205 K USD -26.5%
Payments to Acquire Property, Plant, and Equipment 216 K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -74.8 M USD +22.8%
Lessee, Operating Lease, Liability, to be Paid 209 K USD -26.4%
Property, Plant and Equipment, Gross 1.8 M USD +12.9%
Operating Lease, Liability, Current 84 K USD -82.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1 K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 84 K USD -27%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure +43.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4 K USD -20%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1 K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 69.4 M USD +10.1%
Unrecognized Tax Benefits 5.28 M USD +51.1%
Operating Lease, Payments 200 K USD 0%
Depreciation, Depletion and Amortization 74 K USD +1.37%
Deferred Tax Assets, Net of Valuation Allowance 21 K USD -83.6%
Share-based Payment Arrangement, Expense 5.01 M USD -39.8%
Interest Expense 5.47 M USD +32.3%